Specification of functional cranial placode derivatives from human pluripotent stem cells

• US 10,273,452 B2
• Filed: 05/19/2016
• Issued: 04/30/2019
• Est. Priority Date: 11/21/2013
• Status: Active Grant

• Current Assignee: Memorial Sloan-Kettering Cancer Center
• Original Assignee: Memorial Sloan-Kettering Cancer Center
• Inventors: Chambers, Stuart, Studer, Lorenz, Dincer, Zehra, Zimmer, Bastian
• Primary Examiner(s): Barron, Sean C.
• Application Number:
  US15/159,351
• Publication Number:
  US 20160326491A1
• Time in Patent Office: 1,076 Days
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia
• CPC Class Codes: A61P 27/12 for cataracts
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 39/02 Antidotes
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/02 of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
• CPC Class Codes: A61P 5/06 of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• CPC Class Codes: A61P 5/10 of the posterior pituitary hormones, e.g. oxytocin, ADH
• CPC Class Codes: C07D 211/00 Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
• CPC Class Codes: C07D 243/36 containing an indole or hydrogenated indole ring system
• CPC Class Codes: C07D 307/32 Oxygen atoms
• CPC Class Codes: C12N 2501/119 Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
• CPC Class Codes: C12N 2501/13 : Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
• CPC Class Codes: C12N 2501/155 : Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/41 : Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2501/415 : Wnt; Frizzeled
• CPC Class Codes: C12N 2501/727 : Kinases (EC 2.7.)
• CPC Class Codes: C12N 2501/734 : Proteases (EC 3.4.)
• CPC Class Codes: C12N 2501/998 : Proteins not provided for elsewhere
• CPC Class Codes: C12N 2501/999 : Small molecules not provided for elsewhere
• CPC Class Codes: C12N 2506/02 : from embryonic cells
• CPC Class Codes: C12N 2506/45 : from artificially induced pluripotent stem cells
• CPC Class Codes: C12N 5/0619 : Neurons

Abstract

Cranial placodes are embryonic structures essential for sensory and endocrine organ development. The efficient derivation of cranial placodes from human pluripotent stem cells is disclosed where the timed removal of the BMP inhibitor Noggin, a component of the dual-SMAD inhibition strategy of neural induction, triggers placode induction at the expense of CNS fates. Further fate specification at the pre-placode stage enables the selective generation of placode-derived trigeminal ganglia capable of in vivo engraftment, mature lens fibers and anterior pituitary hormone-producing cells that upon transplantation produce hormones including, but not limited to, human growth hormone and adrenocortiocotropic hormone in vivo. Alternatively, anterior pituitary hormone-producing cells are generated in cell culture systems in vitro.

Claims

1. A method for inducing differentiation of cells comprising

a) contacting a plurality of starting cells with an inhibitor of Small Mothers Against Decapentaplegic (SMAD) protein signaling (“

the SMAD inhibitor”

), wherein the starting cells are selected from the group consisting of multipotent cells, pluripotent cells, and a combination thereof; and

b) contacting the cells with a bone morphogenetic protein (BMP);

c) contacting the cells with a compound selected from the group consisting of BRL-54443, parthenolide, phenanthroline, and combinations thereof; and

wherein the cells are contacted with the SMAD inhibitor and the BMP in an amount effective to induce detectable expression of SIX1 and PAX6 in the plurality of cells.

2. The method of claim 1, wherein the method comprises one or more of the following:

(i) the cells are contacted with the SMAD inhibitor for up to about 11 days, and wherein the cells are contacted with the BMP for up to about 3 days;

(ii) the cells are contacted with an activator of Wnt signaling in an amount effective to induce a detectable level of expression of SIX1 and PAX3 in the plurality of cells;

(iii) the cells are contacted with sonic hedgehog and one or more FGF in an amount effective to induce a detectable level of expression of SIX1 and PITX1 in the plurality of cells; and

(iv) the cells are cultured under conditions effective to induce a detectable level of expression of SIX1 and PITX3 in the plurality of cells.

3. The method of claim 2, wherein the cells are contacted with an activator of Wnt in an amount effective to induce a detectable level of expression of SIX1 and PAX3 in the plurality of cells, and wherein the cells expressing SIX1 and PAX3 are trigeminal placode cells that express a detectable level of GD2, CD57, or a combination thereof.

4. The method of claim 3, further comprising isolating the cells expressing a detectable level of GD2, CD57, or a combination thereof from the plurality of cells.

5. The method of claim 2, wherein the cells are contacted with sonic hedgehog and one or more FGF in an amount effective to induce a detectable level of expression of SIX1 and PITX1 in the plurality of cells, and wherein the cells expressing SIX1 and PITX1 are pituitary placode cells.

6. The method of claim 2, wherein the plurality of cells are cultured under conditions effective to induce a detectable level of expression of SIX1 and PITX3 in the plurality of cells, and wherein the cells expressing SIX1 and PITX3 are lens placode cells.

7. A method for inducing differentiation of cells comprising

a) contacting a plurality of starting cells with a first inhibitor of SMAD protein signaling (“

the first SMAD inhibitor”

), wherein the starting cells are selected from the group consisting of multipotent cells, pluripotent cells, and a combination thereof;

b) contacting the cells with a second inhibitor of SMAD protein signaling (“

the second SMAD inhibitor”

); and

c) contacting the cells with a compound selected from the group consisting of BRL-54443, parthenolide, phenanthroline, and combinations thereof,

wherein the cells are contacted with the first SMAD inhibitor, the second SMAD inhibitor, and the compound in an amount effective to induce detectable expression of SIX1 and PAX6 in the plurality of cells.